Your browser doesn't support javascript.
loading
Impact of Diffuse Large B-Cell Lymphoma on Mammography and Bone Density Testing in Women.
Garg, Rahul; Sambamoorthi, Usha; Tan, Xi; Basu, Soumit K; Haggerty, Treah; Kelly, Kimberly M.
Afiliação
  • Garg R; Department of Pharmacy Practice, College of Pharmacy, Chicago State University, Chicago, IL, 60628, USA.
  • Sambamoorthi U; Department of Pharmaceutical Systems and Policy, School of Pharmacy, West Virginia University, Morgantown, WV, 26506, USA.
  • Tan X; Department of Pharmaceutical Systems and Policy, School of Pharmacy, West Virginia University, Morgantown, WV, 26506, USA.
  • Basu SK; Center for Bone Marrow Transplantation, Geisinger Medical Center, Danville, PA, 17822, USA.
  • Haggerty T; Department of Family Medicine, School of Medicine, West Virginia University, Morgantown, WV, 26506, USA.
  • Kelly KM; Department of Pharmaceutical Systems and Policy, School of Pharmacy, West Virginia University, Morgantown, WV, 26506, USA. kmkelly@hsc.wvu.edu.
J Prim Prev ; 42(2): 143-162, 2021 Apr.
Article em En | MEDLINE | ID: mdl-33710443
ABSTRACT
Women with diffuse large B-cell lymphoma (DLBCL) are at an increased risk of mortality from breast cancer and osteoporosis. However, the impact of DLBCL on rates of mammography and bone density testing (BDT) is unknown. We compared female DLBCL and non-cancer patients utilizing the Surveillance, Epidemiology, and End Results-Medicare dataset to analyze the predictors of mammography and BDT. Guided by the Social Ecological Model (SEM), we used multivariable logistic regressions with inverse probability treatment weighting to examine the association of intrapersonal, interpersonal, healthcare system, and community factors with mammography and BDT. The rates of mammography (59.8%) and BDT (18.5%) in women with DLBCL were similar to those without cancer (60.2% and 19.6%, respectively). After adjusting for the SEM factors, DLBCL patients were less likely to get mammography and BDT than non-cancer patients. The treatments of radiotherapy and stem cell transplant were not associated with either mammography or BDT. DLBCL diagnosis was associated with lower rates of mammography and BDT rates among women with DLBCL, as compared to non-cancer patients. To reduce the morbidity and mortality from breast cancer and fractures in women with DLBCL, providers should increase their recommendations for mammography in those receiving radiotherapy and BDT in stem cell transplant patients.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Densidade Óssea / Linfoma Difuso de Grandes Células B Tipo de estudo: Guideline / Prognostic_studies Limite: Aged / Female / Humans País/Região como assunto: America do norte Idioma: En Revista: J Prim Prev Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Densidade Óssea / Linfoma Difuso de Grandes Células B Tipo de estudo: Guideline / Prognostic_studies Limite: Aged / Female / Humans País/Região como assunto: America do norte Idioma: En Revista: J Prim Prev Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos